Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer Article

cited authors

  • Refaat, Tamer; Choi, Mehee; Gaber, Germaine; Kiel, Krystyna; Mehta, Minesh; Gradishar, William; Small, William

fiu authors

publication date

  • October 1, 2014

keywords

  • ANGIOGENESIS
  • BLOOD-VESSELS
  • CHEMOTHERAPY
  • COMBINATION
  • ENDOTHELIAL GROWTH-FACTOR
  • Life Sciences & Biomedicine
  • OSTEONECROSIS
  • Oncology
  • PHASE-III
  • SURVIVAL
  • Science & Technology
  • THERAPY
  • TRIAL
  • bevacizumab
  • breast cancer
  • cost-effectiveness

Digital Object Identifier (DOI)

start page

  • 480

end page

  • 485

volume

  • 37

issue

  • 5